Ovarian cancer vaccine receives Notice of Allowance from USPTO

Biotech company Anixa Biosciences has received a Notice of Allowance for a key patent application covering its ovarian cancer vaccine technology from the United States Patent and Trademark Office (USPTO).

Anixa’s ovarian cancer vaccine uses a novel approach to preventing and treating ovarian cancer, particularly among high-risk populations such as those carrying BRCA mutations or with a family history of the disease.

The patent includes broad claims related to methods of eliciting an immune response targeting Anti-Mullerian Hormone Receptor, Type II (AMHR2), a promising target for ovarian cancer prevention and treatment.

Dr. Amit Kumar, chairman and CEO of Anixa Biosciences, said: “Receiving this Notice of Allowance from the USPTO is a significant milestone in our mission to develop a preventative and therapeutic ovarian cancer vaccine.

“The allowed claims provide broad protection for the various components and delivery mechanisms of our vaccine technology.

“This strengthens our intellectual property position and supports the continued advancement of our programme.”

The allowed claims include methods of administering an immunogenic composition comprising a nucleic acid encoding the AMHR2 polypeptide, specifically the extracellular domain of human AMHR2, to elicit an AMHR2-specific immune response.